Effect of high-dose erythropoietin on graft function after kidney transplantation: a meta-analysis of randomized controlled trials.

Autor: Xin H; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Ge YZ; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Wu R; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Yin Q; Department of Pharmacology, Nanjing Medical University School of Pharmacy, 140 Hanzhong Road, 210029 Nanjing, PR China; Central Laboratory, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Zhou LH; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Shen JW; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Lu TZ; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Hu ZK; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Wang M; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Zhou CC; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Wu JP; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Li WC; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Zhu JG; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China., Jia RP; Center for Renal Transplantation, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China; Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, 210006 Nanjing, PR China. Electronic address: urojiarp@126.com.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2015 Feb; Vol. 69, pp. 29-33. Date of Electronic Publication: 2014 Nov 06.
DOI: 10.1016/j.biopha.2014.10.029
Abstrakt: Purpose: Current evidence suggests that preconditioning with erythropoietin (EPO) can protect against ischemia reperfusion injury in rodents. However, randomized controlled trials (RCTs) assessing the efficacy and safety of high-dose EPO in kidney transplantation have yielded inconclusive results. Herein, we performed a meta-analysis of RCTs to assess whether the administration of high-dose EPO can improve graft function and the potential adverse events.
Methods: Relevant RCT studies that investigated high-dose EPO on graft function after kidney transplantation were comprehensively searched in Pubmed, Embase, and Cochrane Library until July 10, 2014. All statistical analyses were performed using Review Manager 5.0 and STATA 12.0.
Results: A total of 4 RCTs involving 356 patients were identified. Comprehensively, a trend of reduction in the incidence of delayed graft function could be observed in the EPO group (EPO vs. placebo groups: RR=0.88); however, the result did not reach the significance level (95% CI, 0.72-1.08; P=0.21). Furthermore, no significant difference in the incidences of adverse events was observed between the two groups.
Conclusions: The current meta-analysis indicates that the administration of high-dose EPO is, to some extent, prone to protect kidney function without increasing the susceptibility to adverse events.
(Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: